Latest Supply Chain Expansion News

Supply Network Limited has reported a strong preliminary FY2026 with $403.1 million in sales and a 44-cent fully franked final dividend, reflecting solid profit growth despite Middle East disruptions. The company is advancing major branch expansions and IT upgrades to fuel future growth.

Metallium Ltd has secured a strategic partnership with ElementUSA to deploy its Flash Joule Heating technology for recovering gallium and scandium from red mud in Louisiana, backed by US$10.1 million in non-dilutive funding. This collaboration positions Metallium at the forefront of the US critical minerals supply chain expansion.

Clarity Pharmaceuticals has bolstered its financial position with a $203 million institutional placement and reported positive Phase II trial results for its lead prostate cancer diagnostic, Cu-SAR-bisPSMA. The company also expanded its pipeline with promising preclinical data on a pan-cancer agent and secured a key copper-67 supply agreement to support future commercialisation.

Lynas Rare Earths delivered record quarterly sales revenue of A$200.2 million in Q1 FY26, bolstered by a successful $932 million equity raise and strategic partnerships aimed at securing critical rare earth supply chains outside China.

BPH Global has inked a two-year commercial framework agreement with the Maluku provincial government entity to secure a steady seaweed supply and collaborate on a bio-stimulant manufacturing facility, boosting its footprint in Indonesia’s premium seaweed market.

Advanced Braking Technology (ABT) reported robust FY25 financial results marked by revenue growth and improved profitability, while advancing its strategic roadmap focused on mining safety innovations and global market expansion.

Cettire Limited reported FY25 results showing stable sales revenue and a breakeven adjusted EBITDA despite a challenging luxury goods market. The company’s strategic focus on profitability, supply chain expansion, and emerging markets diversification underpins its resilience.

Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.